CTOs on the Move

aTyr Pharma

www.atyrpharma.com

 
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.atyrpharma.com
  • 3545 John Hopkins Court Suite #250
    San Diego, CA USA 92121
  • Phone: 858.731.8389

Executives

Name Title Contact Details

Funding

aTyr Pharma raised $20M on 11/21/2016
aTyr Pharma raised $45M on 08/28/2017

Similar Companies

Allied Biotech

Allied Biotech is a Ijamsville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Omnicia

Omnicia is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Canadian Bacterial Diseases Network (CBDN)

Canadian Bacterial Diseases Network (CBDN) is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Datavant

Datavant connects healthcare data to eliminate the silos of healthcare information that hold back innovative medical research and improved patient care. We help data owners manage the privacy, security, compliance, and trust required to enable safe data sharing. Datavant`s vision is backed by Roivant Sciences, Softbank, and Founders Fund, and combines technical leadership and healthcare expertise. Datavant is located in the heart of San Francisco`s Financial District.

Elastrin Therapeutics

Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice.